Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Bristol-Myers Squibb Co. (BMY) PT Lowered to $51 at BMO Capital; 'IO NSCLC Complexity Increases'
February 6, 2018 6:51 AM ESTBMO Capital analyst Alex Arfaei lowered his price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $51.00 (from $52.00) while maintaining a Underperform rating.
Arfaei commented, "When the dust finally settles with the 1L-NSCLC data, we see a fragmented market with Merck's Keytruda... More
Bristol-Myers Squibb (BMY) Reports Pivotal Phase 3 CheckMate-227 Study Provides Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination
February 5, 2018 7:09 AM ESTBristol-Myers Squibb Company (NYSE: BMY) today announced that the ongoing Phase 3 CheckMate -227 study met its co-primary endpoint of progression-free survival (PFS) with the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination versus chemotherapy in first-line advanced non-small cell lung cancer (NSCLC) patients whose tumors have high (10 mutations/megabase, mut/mb) tumor mutation burden (TMB),... More
